Effect of Omalizumab in the Skin of Food Allergy Patients
NCT06618963
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this interventional study is to evaluate whether skin barrier abnormalities occur in subjects with a food allergy, as determined by positive oral food challenge (OFC). The main question it aims to answer is whether these skin barrier abnormalities can be reversed by omalizumab. If there is a comparison group: Researchers will compare non-food allergic participants (who do not receive omalizumab) to see if they experience skin barrier abnormalities. All food allergic participants will receive 4 months of Omalizumab treatment as well as two Oral Food Challenges.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Food Allergy
- Food Allergy in Children
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 1 year to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- National Jewish Health
- Last updated on ClinicalTrials.gov
- May 2, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- National Jewish Health · Denver, CO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.